New study reveals how blood cancers outsmart BTK-targeted therapies

Дата публикации: 28-07-2026 17:40:06

Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Team finds way to reverse ovarian cancer’s chemo resistance	5	8	25-06-2026
2	Новое лекарство от агрессивных видов рака крови создают в Петербурге	6	7	17-07-2026
3	Chemotherapy leaves detectable DNA fingerprints in childhood tumors within 18 months	0	8.21	23-07-2026
4	New, improved method to find and isolate the strongest cancer-fighting immune cells	7	8	08-07-2026
5	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
6	Российские ученые создали препарат для снижения побочных эффектов при лечении рака	5	7	05-07-2026
7	Blood test finds hidden pancreatic cancer after treatment	5	8	30-06-2026
8	Family history raises breast cancer risk even when BRCA testing is negative	0	9.88	30-07-2026
9	Same carcinogen, different tumors: Mouse study reveals the role of genetic background	0	6.46	22-07-2026
10	Scientists May Have Found a Cure for Pancreatic Cancer	0	7.46	30-01-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.1. Источник: medicalxpress.com.